

News

Guerbet announces appointment of Thomas McLaughlin as Vice President of North America

26.02.2020 19:28

Princeton, N.J., January 8, 2020– Guerbet, a global specialist in contrast agents and solutions for medical imaging, announced today that Thomas McLaughlin has been appointed Vice President, North America. In this role, McLaughlin will oversee and ensure the growth of Guerbet diagnostic and interventional solutions together with the digital and AI portfolio.

"I'm thrilled to build on Guerbet's successful growth in North America over the last several years to help us solidify leadership and trust with our radiology partners and the patients they treat," stated McLaughlin.

McLaughlin takes on the Vice President role after serving as Guerbet's General Manager of North American Sales and Service, where he led the company's North American sales group to consecutive year-over-year growth. Prior to joining Guerbet, McLaughlin held various Sales Leadership and VP roles both inside and outside the industry, including roles at Nemoto International and E-Z-EM.

"We are delighted that Tom McLaughlin will lead Guerbet's North America Executive team," said David Hale, Guerbet Chief Executive Officer. "From the successful launch of Dotarem® (gadoterate meglumine) in North America seven years ago, to the launch of our interventional imaging business and most recently our entry into the digital solutions space, Tom has the experience, knowledge, leadership, and client expertise to take us into the new decade, increasing Guerbet's visibility and growth as a leading player in medical imaging worldwide."

McLaughlin holds a Radiologic Technologist degree from Temple University, an Associate in Science from Widener University, and both a Bachelor of Science in business and a Master of Business Administration from California Coast University.

ABOUT GUERBET

Guerbet is a pioneer in the contrast-agent field, with more than 90 years' experience, and is a leader in medical imaging worldwide. It offers a comprehensive range of pharmaceutical products, medical devices and services for diagnostic and interventional imaging, to improve the diagnosis and treatment of patients. With 8% of revenue dedicated to R&D and more than 200 employees distributed amongst its four centers in France, Israel and the United States, Guerbet is a substantial investor in research and innovation. Guerbet (GBT) is listed on Euronext Paris (segment B – mid caps) and generated €790 million in revenue in 2018. For more information about Guerbet, please visit www.guerbet.com.



[<- Back to: News](#)